Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
详细信息 查看全文
- 作者：Alice Fabarius ; Lida Kalmanti ; Christian T. Dietz ; Michael Lauseker…
- 关键词：Chronic myeloid leukaemia ; Balanced and unbalanced karyotypes ; Cytogenetics ; Prognosis ; Outcome
- 刊名：Annals of Hematology
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：94
- 期：12
- 页码：2015-2024
- 全文大小：731 KB
- 参考文献：1.Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118(26):6760-768CrossRef PubMed
2.Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al (2003) Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17(2):461-63CrossRef PubMed
3.Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G et al (2010) Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-681PubMed Central PubMed
4.Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290-93CrossRef PubMed
5.O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100(5):1628-633CrossRef PubMed
6.O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC et al (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103(2):451-55CrossRef PubMed
7.Mitelman F, Levan G, Nilsson PG, Brandt L (1976) Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer 18(1):24-0CrossRef PubMed
8.Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107(2):76-4CrossRef PubMed
9.Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872-84CrossRef PubMed
10.Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634-642CrossRef PubMed
11.Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-051CrossRef PubMed
12.Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16(1):53-9CrossRef PubMed
13.Shaffer L, McGowan-Jordan J, Schmid M eds. (2013) ISCN 2013 An international system for human cytogenetic nomenclature. Basel: Karger
14.Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al (2015) Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29(5):1123-132CrossRef PubMed
15.Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M et al (2009) Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 114(24):4939-943CrossRef PubMed
16.Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13(11):1825-832CrossRef PubMed
17.Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172-175CrossRef PubMed
18.Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695-06CrossRef PubMed
19.Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J (2011) Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25(9):1433-438CrossRef PubMed
20.Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850-58CrossRef PubMed
21.Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-f - 作者单位：Alice Fabarius (1)
Lida Kalmanti (1)
Christian T. Dietz (1)
Michael Lauseker (2)
Sébastien Rinaldetti (1)
Claudia Haferlach (3)
Gudrun G?hring (4)
Brigitte Schlegelberger (4)
Martine Jotterand (5)
Benjamin Hanfstein (1)
Wolfgang Seifarth (1)
Mathias H?nel (6)
Claus-Henning K?hne (7)
Hans W. Lindemann (8)
Wolfgang E. Berdel (9)
Peter Staib (10)
Martin C. Müller (1)
Ulrike Proetel (1)
Leopold Balleisen (11)
Maria-Elisabeth Goebeler (12)
Jolanta Dengler (13)
Christiane Falge (14)
Lothar Kanz (15)
Andreas Burchert (16)
Michael Kneba (17)
Frank Stegelmann (18)
Michael Pfreundschuh (19)
Cornelius F. Waller (20)
Karsten Spiekermann (21)
Tim H. Brümmendorf (22)
Matthias Edinger (23)
Wolf-Karsten Hofmann (1)
Markus Pfirrmann (2)
Joerg Hasford (2)
Stefan Krause (24)
Andreas Hochhaus (25)
Susanne Sau?ele (1)
Rüdiger Hehlmann (1)
for the SAKK and the German CML Study Group
1. III. Medizinische Universit?tsklinik, Medizinische Fakult?t Mannheim der Universit?t Heidelberg, Pettenkoferstrasse 22, 68169, Mannheim, Germany
2. Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit?t München, München, Germany
3. MLL Münchner Leuk?mielabor, München, Germany
4. Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Germany
5. Service de génétique médicale, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
6. Klinik für Innere Medizin III, Klinikum Chemnitz, Chemnitz, Germany
7. Klinik für Onkologie und H?matologie, Klinikum Oldenburg, Oldenburg, Germany
8. Klinik für H?matologie und Onkologie, St.-Marien-Hospital Hagen, Hagen, Germany
9. Medizinische Klinik A, Universit?tsklinikum Münster, Münster, Germany
10. Klinik für H?matologie und Onkologie, St.-Antonius-Hospital Eschweiler, Eschweiler, Germany
11. Abteilung für H?matologie-Onkologie, Evangelisches Krankenhaus Hamm, Hamm, Germany
12. Medizinische Klinik und Poliklinik II, Universit?tsklinikum Würzburg, Würzburg, Germany
13. Abteilung Innere Medizin V, Medizinische Klinik, Universit?tsklinikum Heidelberg, Heidelberg, Germany
14. Medizinische Klinik 5, Klinikum Nürnberg Nord, Nord, Germany
15. Medizinische Klinik, Abteilung II, Universit?tsklinikum Tübingen, Tübingen, Germany
16. Klinik für Innere Medizin, Schwerpunkt H?matologie, Onkologie und Immunologie, Universit?tsklinikum Marburg, Marburg, Germany
17. II. Medizinische Klinik und Poliklinik, Universit?tsklinikum Schleswig-Holstein, Kiel, Germany
18. Klinik für Innere Medizin III, Universit?tsklinikum Ulm, Ulm, Germany
19. Klinik für Innere Medizin I, Universit?tsklinikum des Saarlandes, Homburg, Germany
20. Abteilung Innere Medizin I, Universit?tsklinikum Freiburg, Freiburg, Germany
21. Medizinische Klinik und Poliklinik III, Klinikum der Universit?t München, München, Germany
22. Medizinische Klinik IV, Uniklinik RWTH Aachen, Aachen, Germany
23. Klinik und Poliklinik für Innere Medizin III, Universit?tsklinikum Regensburg, Regensburg, Germany
24. Medizinische Klinik 5, Universit?tsklinikum Erlangen, Erlangen, Germany
25. Abteilung für H?matologie/Onkologie, Universit?tsklinikum Jena, Jena, Germany - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Hematology
Oncology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0584
文摘
Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major route ACA are almost always unbalanced, it is unclear whether other unbalanced ACA at diagnosis also confer an unfavourable prognosis. On the basis of 1348 Philadelphia chromosome-positive chronic phase patients of the randomized CML study IV, we examined the impact of unbalanced minor route ACA at diagnosis versus major route ACA on prognosis. At diagnosis, 1175 patients (87.2 %) had a translocation t(9;22)(q34;q11) and 74 (5.5 %) a variant translocation t(v;22) only, while a loss of the Y chromosome (?Y) was present in addition in 44 (3.3 %), balanced or unbalanced minor route ACA each in 17 (1.3 %) and major route ACA in 21 (1.6 %) cases. Patients with unbalanced minor route ACA had no significantly different cumulative incidences of complete cytogenetic remission or major molecular remission and no significantly different progression-free survival (PFS) or overall survival (OS) than patients with t(9;22), t(v;22), ?Y and balanced minor route karyotypes. In contrast, patients with major route ACA had a shorter OS and PFS than all other groups (all pairwise comparisons to each of the other groups: p?≤-.015). Five-year survival probabilities were for t(9;22) 91.4 % (95 % CI 89.5-3.1), t(v; 22) 87 % (77.2-4.3), ?Y 89.0 % (76.7-7.0), balanced 100 %, unbalanced minor route 92.3 % (72.4-00) and major route 52.2 % (28.2-5.5). We conclude that only major route, but not balanced or unbalanced minor route ACA at diagnosis, has a negative impact on prognosis of CML. Keywords Chronic myeloid leukaemia Balanced and unbalanced karyotypes Cytogenetics Prognosis Outcome